Cleveland BioLabs (NASDAQ:CBLI) said Thursday that its experimental medicine administered with chemotherapy showed complete tumour regression in mice.
The results were presented at the Advances in Neuroblastoma Research Association meeting on June 20, in Toronto.
The presentation featured a series of experiments conducted in collaboration between scientists at Children’s Cancer Institute Australia, Roswell Park Cancer Institute and Cleveland BioLabs' subsidiary, Incuron.
The drug, known as CBL-0137, was used in combination with chemotherapy in animal models with neuroblastoma.
Neuroblastoma is a malignant cancerous tumour that develops from nerve tissue. It usually occurs in infants and children.
According to results, when administered separately, CBL-0137 and chemotherapy revealed a delay in tumour development and survival progression. The company noted that neither treatment alone was capable of causing complete tumour regression.
Cleveland also said, however, that when the drug was given orally or intravenously with other chemo drugs, complete regression was achieved in 100 per cent of the study animals.
“We are very excited by the outcome of these studies,” executive director Michelle Haber at Children’s Cancer Institute Australia said in a statement.
"We have been working with this model for many years and have tested numerous therapeutic approaches, but this is the first time we have achieved complete regression in tumour-bearing animals."
An investigational new drug application for clinical testing for oral administration of the drug was recently opened with the regulatory authority of the Russian Federation.
Pre-clinical studies with the intravenous formulation of the drug are being performed in preparation for filing an investigational new drug application in the U.S.
Cleveland BioLabs is a clinical-stage biotechnology company with a focus on oncology and orphan drug development.